| Autor: |
Friedrich, Stölzel, Sarah E, Fordham, Devi, Nandana, Wei-Yu, Lin, Helen J, Blair, Claire J, Elstob, Hayden L, Bell, Brigitte, Mohr, Leo, Ruhnke, Desiree, Kunadt, Claudia, Dill, Daniel A, Allsop, Rachel E, Piddock, Emmanouela-Niki, Soura, Catherine Vida, Park, Mohd, Fadly, Thahira, Rahman, Abrar A, Alharbi, Manja, Wobus, Heidi, Altmann, Christoph, Röllig, Lisa, Wagenführ, Gail L, Jones, Tobias, Menne, Graham H, Jackson, Helen J, Marr, Jude, Fitzgibbon, Kenan, Onel, Manja, Meggendorfer, Amber, Robinson, Zuzanna, Bziuk, Emily, Bowes, Olaf, Heidenreich, Torsten, Haferlach, Sara, Villar, Beñat, Ariceta, Rosa, Ayala Diaz, Steven J, Altschuler, Lani, Wu, Felipe, Prosper, Pau, Montesinos, Joaquin, Martinez-Lopez, Martin, Bornhäuser, James M, Allan |
| Rok vydání: |
2022 |
| Zdroj: |
JCI insight. |
| ISSN: |
2379-3708 |
| Popis: |
Precision medicine can significantly improve outcomes for cancer patients, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here we describe somatic biallelic TET2 mutations in an elderly patient with acute myeloid leukemia (AML) that was chemoresistant to anthracycline and cytarabine (Ara-C), but acutely sensitive to 5'-azacitidine (5'-Aza) hypomethylating monotherapy resulting in long-term morphological remission. Given the role of TET2 as a regulator of genomic methylation, we hypothesized that mutant TET2 allele dosage affects response to 5'-Aza. Using an isogenic cell model system and an orthotopic mouse xenograft, we demonstrate that biallelic TET2 mutations confer sensitivity to 5'-Aza compared to cells with monoallelic mutation. Our data argue in favor of using hypomethylating agents for chemoresistant disease or as first line therapy in patients with biallelic TET2-mutated AML and demonstrate the importance of considering mutant allele dosage in the implementation of precision medicine for cancer patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
